Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial - PubMed
5 days ago
- #pembrolizumab
- #immunotherapy
- #melanoma
- Adjuvant pembrolizumab was analyzed for its effect on new skin cancers in high-risk stage II melanoma patients.
- The study involved 976 participants, with a median follow-up of 52.8 months, comparing pembrolizumab to placebo.
- New skin cancers were less frequent in the pembrolizumab group (7.6%) compared to placebo (11.5%).
- Recurrence-free survival (RFS) benefit was maintained with pembrolizumab even after accounting for new primary melanomas.
- Immune-mediated severe skin reactions were infrequent (3.3% in pembrolizumab vs. 0.6% in placebo) and manageable.
- The findings support the use of adjuvant pembrolizumab in high-risk stage II melanoma.